Christopher D. Maggiore - 05 Jun 2024 Form 4 Insider Report for Zivo Bioscience, Inc. (ZIVO)

Role
Director, 10%+ Owner
Signature
/s/ Christopher D. Maggiore
Issuer symbol
ZIVO
Transactions as of
05 Jun 2024
Net transactions value
+$649,090
Form type
4
Filing time
06 Jun 2024, 18:30:33 UTC
Previous filing
02 Jan 2024
Next filing
13 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZIVO Common Stock Award +36,630 +11% 373,446 05 Jun 2024 Direct F3
transaction ZIVO Common Stock Award $649,090 +81,544 +22% $7.96 454,990 05 Jun 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Disposed to Issuer -1,902 -100% 0 05 Jun 2024 Common Stock 1,902 $26.88 Direct F1, F2, F3
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Disposed to Issuer -7,000 -100% 0 05 Jun 2024 Common Stock 7,000 $33.00 Direct F1, F2, F3
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Disposed to Issuer -2,632 -100% 0 05 Jun 2024 Common Stock 2,632 $21.66 Direct F1, F2, F3
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Disposed to Issuer -707 -100% 0 05 Jun 2024 Common Stock 707 $17.16 Direct F1, F2, F3
transaction ZIVO Nonstatutory Stock Option to Purchase Common Stock Disposed to Issuer -3,626 -100% 0 05 Jun 2024 Common Stock 3,626 $16.74 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023.
F2 The canceled options were fully vested.
F3 The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock.
F4 The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 6/12/2023 and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service on each applicable vesting date.